NAT2 and breast cancer: However, in the case of BC, Zhao and colleagues (2007) found that NAT2 (N-acetyltransferase 2) slow genotype increased about 37% BC risk in the Caucasian population but did not impact the isothiocyanate protective anticancer effect [64].